Dimerix acquires kidney injury drug DMX-652 from Mission Therapeutics as Arpeggio appears to wind down acute kidney program

Dimerix, an Australian clinical-stage biopharmaceutical company, has acquired the Phase 2-ready acute kidney injury (AKI) drug candidate DMX-652 (formerly MTX652) from UK-based Mission Therapeutics for an upfront payment of $5 million and up to $287 million in potential milestone payments, totaling up to $292 million including royalties and sales milestones.

DMX-652 is a selective USP30 inhibitor that supports mitochondrial quality control in injured kidney cells and is being developed as an oral once daily capsule for the prevention of AKI, a condition with significant unmet medical need and an estimated global market of $3.5 billion in 2026.

The acquisition includes the assignment of the composition-of-matter patent, an open US Investigational New Drug (IND) application, an FDA-cleared Phase 2 clinical trial protocol, and sufficient GMP drug supply for the planned study, which will evaluate DMX-652 in approximately 160 patients at high risk of AKI following cardiac surgery.

Mission Therapeutics is divesting the kidney program to focus on its Parkinson’s disease asset MTX325, indicating a strategic shift away from acute kidney disease and suggesting a winding down of Arpeggio/Mission’s presence in that space, while Dimerix strengthens its renal franchise beyond its lead FSGS program with DMX-200 and expands into acute kidney injury.

Sources:

Dimerix buys Mission's kidney disease prospect in $292M ...

DIMERIX EXPANDS PIPELINE WITH ACQUISITION OF ...

Dimerix acquires Phase 2-ready acute kidney injury drug ...

UK's Mission divests kidney drug to Dimerix for $292m

Dimerix acquires Phase 2-ready asset for acute kidney injury